ArticleEuropean journal of haematology2026
Complications in Central Venous Access Devices in Paediatric Cancer Care: A Global Cross-Sectional Survey.
Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Complications in Central Venous Access Devices in Paediatric Cancer Care: A Global Cross-Sectional Survey.European journal of haematology · 2026Article
- Central venous access device-associated complication costs in paediatric cancer care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo examine global practices for identifying and managing central venous access device (CVAD) complications-catheter-associated bloodstream infection (CABSI), thrombosis, and occlusion-in paediatric cancer care, comparing patterns between high- and other-income countries.
methodsA cross-sectional international survey was conducted from 2022 to 2023 and analysed 2024 to 2025. Clinicians involved in paediatric CVAD cancer care were recruited through global networks.
resultsA total of 161 respondents from 38 countries completed the complication section, including 102 (63.4%) from high-income and 59 (36.6%) from other-income countries (lower- and upper-middle income). For CABSI, blood culture was the main diagnostic method (122 [75.8%]; high-income: 87 [85.3%], other-income: 35 [59.3%]). Differential time to positivity was more often reported in other-income settings (33 [55.9%] vs. 35 [34.3%]), who also more frequently initiated antibiotics based on nonspecific or immediate criteria. CABSI treatment varied, with intravenous antibiotics (68 [60.7%]) and catheter removal (47 [42.0%]) most reported. For thrombosis, anticoagulation before line removal was common (88 [54.7%]), and alteplase use was higher in high-income countries (76 [74.5%] vs. 19 [32.2%]). Thrombolytic agents were the most reported treatment for occlusion (103 [64.0%]), especially in high-income countries (77 [75.5%] vs. 26 [44.1%]).
conclusionsCVAD complication management varies by country income level, highlighting the need for context-adapted guidelines, training, and equitable access to key resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.